CAR-TCR 2020细胞与基因治疗创新峰会暨亚太新药研发领袖峰会将于2020年10月15日至16日在上海浦东锦江汤臣洲际大酒店举行。

本次大会围绕细胞基因治疗商业化和产业化、CAR-T生产工艺、罕见病AAV基因治疗产品开发、新冠COVID-19细胞疗法、CAR-T/TCR-T/CAR-NK临床开发等主题进行深度探讨，来自政府监管机构、行业协会、科研院校、海内外生物医药领域专家共计350余名代表将共襄盛会。

金秋十月，三优生物携集成化创新CAR-T研发服务和一体化抗体药物研发服务亮相本次会议。三优集成化创新CAR-T研发平台极致高效，从靶点筛选开始，经过scFv抗体设计、CAR结构设计及构建、病毒包装和CAR-T细胞的产生、体外药效检测、动物模型体内药效检测等完整环节，从靶点到临床候选CAR-T，带来高品质、高成功率、便捷的一体化产品开发体验。

▎三优信息：

三优生物展位号：#B3

大会时间：2020年10月15-16日

大会地点：上海浦东锦江汤臣洲际大酒店（上海市浦东新区张杨路777号）

▎大会日程：

10月15日

Future Directions of Cell & Gene Therapy and Innovation in China

上午8:45-8:50

欢迎致辞

上午8:50-9:20

Engineering TCR-based Immunotherapy against Cancer and Viral Infection

Dr. Xin Lin

Professor and Chairman, School of Medicine, Department of Basic Medical Sciences, Tsinghua University
Founder, China Immunotech ( Beijing ) Biotechnology Co., Ltd.

上午9:20-9:50

Translating and Developing Novel Cell Therapy Product for Fighting against COVID-19

Dr. Yu Zhang
Senior Vice President and Chief Scientific Officer, VCANBIO Cell & Gene Engineering Co., Ltd.

上午9:50-10:20

Developing AAV-based Gene Therapy Products in China, First China International AAV-Based Gene Therapy in Leber’s Hereditary Optic Neuropathy

Dr. Alvin Luk

Chief Executive Officer, Neurophth Therapeutics

上午10:20-10:50

From Manufacturing to Clinical: How Cytiva Accelerate your Cell Therapy Process with Automated, Closed and Scalable Module System

Dr. Yulong Cheng
Product Manager Asia Cell Therapy, Cytiva

上午10:50-11:00

茶歇及展台访问

上午11:00-11:45

Panel Discussion:
Strengthening Collaboration for Development & Commercialization CAR-T Cell Therapy in China 

Moderator:
Dr. Yu Zhang
Senior Vice President and Chief Scientific Officer, VCANBIO Cell & Gene Engineering Co., Ltd.

Panelists:
Mr. Tony Liu
Chief Executive Officer & Chief Financial Officer, Cellular Biomedicine Group
Mr. Xiaoliang Sang
Regional Commercial GM-Asia Cell & Gene Therapy, Cytiva

Dr. Ting He
Chief Executive Officer, ImmunoChina Pharmaceuticals
Dr. Lyu Lulu
Chief Executive Officer, Juventas Cell Therapy
Dr. Lei Zhang
Senior Director of Discovery, Fosun Kite Biotechnology
Dr. Jijun Yuan

Chief Executive Officer, Shanghai Genbase Biotechnology

上午11:45-12:15

The Demand of Novel Equipment for New Concept Cell Therapy Product

Dr. Lei Zhang
Senior Director of R&D, Fosun Kite Biotechnology

上午12:15-12:45

The Investment and Venture Opportunities in Gene Therapy

Dr. Adam Zhao
Chairman and CEO,
Beijing Anlong Gene Medicine Technology

下午12:45-14:00

午宴及展台访问

下午14:00-14:30

Development Safe and Potent CD19 CAR-T Cell Therapy in China targeting Hematological Malignancies

Dr. Ting He
Chief Executive Officer, ImmunoChina Pharmaceuticals

下午14:30-15:00

First-in-class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-lymphoblastic leukemia/lymphoma

Dr. Lin Yang
Founder & Chief Executive Officer, PersonGen BioTherapeutics

下午15:00-15:30

Precision Immunotherapy: Development BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma
Dr. Wen (Maxwell) Wang
Chief Medical Officer, IASO Biotherapeutics

下午15:30-16:00

分布式个性化细胞药品智能生产

陈皓 先生

创始人, CEO/总工程师,
英诺维尔智能科技（苏州）有限公司

下午16:00-16:20

茶歇及展台访问

下午16:20-16:50

Surface Density of CAR Molecules Modulate the Kinetics of CAR-T Cells In Vivo

Dr. Jianqiang Li
Founder and Chief Scientific Officer, Hebei Senlang Biotech

下午16:50-17:20

CAR T Process Development and in Process and Batch Releasing Assay Development

Dr. Xinpo Jiang
Senior Director, Analytical/Process Validation/QC/QA, Legend Biotech

下午17:20-18:00

Panel Discussion:
CAR T Process Development and Quality advancements in CAR-T cell manufacturing

Moderator:
Dr. Xinpo Jiang
Senior Director, Analytical/Process Validation/QC/QA, Legend Biotech

Panelists:

Dr. Lei Zhang
Senior Director of Discovery, Fosun Kite Biotechnology
Mr. James Chen
Chief Executive Officer, INNOVEL

Dr. Lin Yang
Founder & Chief Executive Officer, PersonGen BioTherapeutics

下午18:00-18:30

Novel Proceeding about Targeting CD 30 CAR-T Therapy for Lymphoma

Dr. Tongcun Zhang
Chief Executive Officer, Wuhan Bio-Raid Biotechnology

下午18:30

会议第一天结束

10月16日

Future Directions of Cell & Gene Therapy and Innovation in China

上午8:45-9:00

欢迎致辞

上午9:00-9:30

Precision TCR Redirected T Cell Immunity Treating Solid Tumour

Dr. Yi Li
President & Chief Scientific Officer, Guangdong Xiangxue Life Sciences

上午9:30-10:00

Solid Tumour CAR-T Barriers and Solutions

Dr. Enxiu Wang

Founder and Chief Executive Officer

Nanjing CART Medical Technology

上午10:00-10:30

The Latest Advancement in T-cell-based Cancer Immunotherapy

Dr. Mingjun Wang
Executive President, Shenzhen Institute for Innovation and Translational Medicine

上午10:30-11:00

The Application and Advantages of Nano-bodies in Immuno-cellular Therapy Development

Dr. Jishuai Zhang

Chief Scientific Officer, The Pregene Biopharma Company

上午11:00-11:15

茶歇及展台访问

上午11:15-11:45

Clinical Development of CAR T Cell Therapy & Next Generation CAR T Cells 

Dr. Wei Wang
Vice President of Clinical Development, CARsgen Therapeutics

上午11:45-12:15

通过造血干细胞中的基因编辑技术治疗地中海贫血

吴宇轩 博士
研发副总裁, 上海邦耀生物科技有限公司

上午12:15-12:45

溶瘤病毒OH2的研究进展

刘滨磊 教授

董事长, 武汉滨会生物科技股份有限公司

下午12:45-14:00

午宴及展台访问

下午14:00-14:30

基于非病毒载体的CAR-T 细胞肿瘤治疗
孙艳 女士

副总裁, 细胞药物BU总经理, 上海细胞治疗集团

下午14:30-15:00

Next Generations of CAR-T Technologies –TruUCAR™ and FasTCAR™
Dr. Xinxin Wang
Group Leader for TruUCAR Platform Development, Gracell Biotechnologies

下午15:00-15:30

What can Flow Cytometry Do for CAR-T

王卉 博士
检验科负责人( 副院长级 ), 陆道培医疗集团

下午15:30-16:00

茶歇及展台访问

下午16:00-16:30

Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors

Dr. Dayu Hu

Chief Operating Officer, Asclepius Technology Company Group

下午16:30-17:00

DNT 细胞技术-从基础研究到临床治疗肿瘤细胞药的研发
杨黎明 博士
董事长兼首席执行官, 浙江瑞顺生物技术有限公司

下午17:00-17:30

Progress on TCR-T Development and Solid Tumor Treatment

Dr. Yi Zhu
China Head, T-Cure Bioscience

下午17:45

会议第二天结束